SUPN

+ Watchlist + Portfolio

Supernus Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $48.54
52-Week Range: $42.45 – $59.68
Market Cap: $2.76B
P/E (TTM): —
EPS (TTM): -1.88
Dividend Yield: —

Advanced Metrics

Price/Book: 2.68
PEG Ratio: —
Return on Equity: -10.49%
Return on Assets: 0.39%
Gross Margin: 72.89%
Operating Margin: -2.48%
Profit Margin: -13.23%
Current Ratio: 2.08
Debt/Equity: 0.04
Total Debt: $40.17M
Free Cash Flow: $84.61M
Revenue Growth: 32.40%
Earnings Growth: —
Enterprise Value: $2.43B

SUPN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$667.24M	$607.52M	$661.82M	$718.95M
Cost of Revenue	$87.22M	$83.78M	$77.91M	$74.56M
Gross Profit	$580.02M	$523.74M	$583.91M	$644.39M
Research & Development	$74.55M	$91.59M	$108.80M	$106.23M
Selling, General & Admin	$377.22M	$336.36M	$321.58M	$485.56M
Operating Expenses	$534.40M	$510.34M	$508.36M	$681.25M
Operating Income	$45.61M	$13.40M	$75.56M	-$36.86M
EBITDA	$153.36M	$90.04M	$178.28M	$42.53M
Pretax Income	$60.74M	$2.77M	$97.87M	-$49.03M
Income Tax	$32.00K	$1.45M	$24.00M	-$10.48M
Net Income	$60.71M	$1.32M	$73.86M	-$38.55M
Diluted EPS	1.04	0.02	1.32	-0.68
Diluted Shares	61.68M	55.51M	55.96M	56.45M

SUPN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$93.12M	$75.05M	$69.33M	$128.45M
Receivables	$165.50M	$144.16M	$142.08M	$187.80M
Inventory	$91.54M	$77.41M	$54.29M	$82.39M
Current Assets	$734.15M	$493.11M	$686.07M	$644.18M
Total Assets	$1.70B	$1.28B	$1.37B	$1.45B
Current Liabilities	$687.96M	$290.20M	$292.40M	$338.17M
Total Debt	$444.76M	$41.53M	$34.27M	$40.98M
Total Liabilities	$816.30M	$356.16M	$332.34M	$390.93M
Retained Earnings	$481.25M	$482.56M	$556.43M	$517.88M
Shareholders' Equity	$886.20M	$921.52M	$1.04B	$1.06B
Working Capital	$46.19M	$202.92M	$393.67M	$306.01M
Net Debt	$308.85M	—	—	—

SUPN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$116.83M	$111.08M	$171.95M	$47.33M
Capital Expenditure	-$412.00K	-$551.00K	-$725.00K	-$1.34M
Free Cash Flow	$116.41M	$110.53M	$171.23M	$45.99M
Depreciation & Amortisation	$85.54M	$84.86M	$80.41M	$91.56M
Stock-Based Compensation	$17.57M	$26.76M	$27.75M	$33.05M
Investing Cash Flow	-$216.66M	$268.73M	-$189.87M	$4.11M
Financing Cash Flow	-$10.48M	-$397.88M	$12.19M	$9.13M
Net Change in Cash	-$110.31M	-$18.07M	-$5.72M	$60.57M

SUPN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$149.82M	$165.45M	$192.10M	$211.57M	$207.71M
Cost of Revenue	$15.76M	$16.83M	$18.96M	$23.01M	$23.39M
Gross Profit	$134.06M	$148.63M	$173.14M	$188.56M	$184.31M
Research & Development	$26.93M	$22.11M	$29.37M	$27.83M	$39.44M
Selling, General & Admin	$89.94M	$93.55M	$179.68M	$122.39M	$125.17M
Operating Expenses	$136.66M	$136.49M	$233.37M	$174.74M	$190.25M
Operating Income	-$2.60M	$12.14M	-$60.23M	$13.82M	-$5.94M
EBITDA	$17.79M	$33.50M	-$35.42M	$26.67M	$20.19M
Pretax Income	-$5.83M	$16.67M	-$57.95M	-$1.91M	-$5.95M
Income Tax	$6.00M	-$5.83M	-$12.84M	$2.19M	-$3.66M
Net Income	-$11.83M	$22.50M	-$45.12M	-$4.11M	-$2.29M
Diluted EPS	-0.21	0.40	-0.80	-0.07	-0.04
Diluted Shares	55.86M	56.64M	56.55M	57.34M	57.65M

SUPN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$115.85M	$144.71M	$151.37M	$128.45M	$184.87M
Receivables	$145.64M	$140.83M	$171.25M	$187.80M	$182.18M
Inventory	$49.42M	$44.02M	$79.40M	$82.39M	$87.06M
Current Assets	$687.58M	$738.87M	$593.89M	$644.18M	$731.58M
Total Assets	$1.35B	$1.38B	$1.42B	$1.45B	$1.50B
Current Liabilities	$281.77M	$286.36M	$330.63M	$338.17M	$373.93M
Total Debt	$32.30M	$31.77M	$42.21M	$40.98M	$40.90M
Total Liabilities	$316.58M	$318.50M	$370.09M	$390.93M	$423.92M
Retained Earnings	$544.60M	$567.10M	$521.98M	$517.88M	$515.58M
Shareholders' Equity	$1.03B	$1.06B	$1.05B	$1.06B	$1.08B
Working Capital	$405.81M	$452.51M	$263.26M	$306.01M	$357.65M

SUPN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$30.60M	$58.53M	-$61.66M	$19.86M	$66.52M
Capital Expenditure	-$327.00K	-$455.00K	-$129.00K	-$427.00K	—
Free Cash Flow	$30.27M	$58.08M	-$61.79M	$19.43M	$66.52M
Depreciation & Amortisation	$20.38M	$21.36M	$24.81M	$25.02M	$26.13M
Stock-Based Compensation	$8.07M	$7.51M	$7.83M	$9.65M	$8.48M
Investing Cash Flow	$37.32M	-$30.61M	$48.71M	-$51.31M	-$19.22M
Financing Cash Flow	-$21.40M	$935.00K	$21.07M	$8.53M	$9.12M
Net Change in Cash	$46.52M	$28.86M	$8.11M	-$22.92M	$56.42M

Market Snapshot

About

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company markets FDA-approved medications for epilepsy, ADHD, and other neurological conditions. Supernus has a pipeline of additional product candidates in various stages of clinical development.